Effect of intranasal rosiglitazone on airway inflammation and remodeling in a murine model of chronic asthma
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Asthma is characterized by airway hyperresponsiveness, inf lammation, and remodeling. Peroxisome proliferator-activated receptors have been reported to regulate inflammatory responses in many cells. In this study, we examined the effects of intranasal rosiglitazone on airway remodeling in a chronic asthma model. Methods: We developed a mouse model of airway remodeling, including smooth muscle thickening, in which ovalbumin (OVA)-sensitized mice were repeatedly exposed to intranasal OVA administration twice per week for 3 months. Mice were treated intranasally with rosiglitazone with or without an antagonist during OVA challenge. We determined airway inflammation and the degree of airway remodeling by smooth muscle actin area and collagen deposition. Results: Mice chronically exposed to OVA developed sustained eosinophilic airway inflammation, compared with control mice. Additionally, the mice developed features of airway remodeling, including thickening of the peribronchial smooth muscle layer. Administration of rosiglitazone intranasally inhibited the eosinophilic inflammation significantly, and, importantly, airway smooth muscle remodeling in mice chronically exposed to OVA. Expression of Toll-like receptor (TLR)-4 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κB) was increased in the OVA group and decreased in the rosiglitazone group. Co-treatment with GW9660 (a rosiglitazone antagonist) and rosiglitazone increased the expression of TLR-4 and NF-κB. Conclusions: These results suggest that intranasal administration of rosiglitazone can prevent not only airway inf lammation but also airway remodeling associated with chronic allergen challenge. This beneficial effect is mediated by inhibition of TLR-4 and NF-κB pathways.
Abstract
Background/Aims: Asthma is characterized by airway hyperresponsiveness, inf lammation, and remodeling. Peroxisome proliferator-activated receptors have been reported to regulate inflammatory responses in many cells. In this study, we examined the effects of intranasal rosiglitazone on airway remodeling in a chronic asthma model. Methods: We developed a mouse model of airway remodeling, including smooth muscle thickening, in which ovalbumin (OVA)-sensitized mice were repeatedly exposed to intranasal OVA administration twice per week for 3 months. Mice were treated intranasally with rosiglitazone with or without an antagonist during OVA challenge. We determined airway inflammation and the degree of airway remodeling by smooth muscle actin area and collagen deposition. Results: Mice chronically exposed to OVA developed sustained eosinophilic airway inflammation, compared with control mice. Additionally, the mice developed features of airway remodeling, including thickening of the peribronchial smooth muscle layer. Administration of rosiglitazone intranasally inhibited the eosinophilic inflammation significantly, and, importantly, airway smooth muscle remodeling in mice chronically exposed to OVA. Expression of Toll-like receptor (TLR)-4 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κB) was increased in the OVA group and decreased in the rosiglitazone group. Co-treatment with GW9660 (a rosiglitazone antagonist) and rosiglitazone increased the expression of TLR-4 and NF-κB. Conclusions: These results suggest that intranasal administration of rosiglitazone can prevent not only airway inf lammation but also airway remodeling associated with chronic allergen challenge. This beneficial effect is mediated by inhibition of TLR-4 and NF-κB pathways.
참고문헌 (38)
- Bateman ED, "Global strategy for asthma management and prevention: GINA executive summary", Eur Respir J, 31, pp.143~178 (2008)
- Wiggs BR, "A model of airway narrowing in asthma and in chronic obstructive pulmonary disease", Am Rev Respir Dis, 145, pp.1251~1258 (1992)
- Zuyderduyn S, "Treating asthma means treating airway smooth muscle cells", Eur Respir J, 32, pp.265~274 (2008)
- Chan V, "Extracellular matrix regulates enhanced eotaxin expression in asthmatic airway smooth muscle cells", Am J Respir Crit Care Med, 174, pp.379~385 (2006)
- Brightling CE, "The CXCL10", CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle, 2005, pp.171, 1103~1108
- El-Shazly A, "Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma", J Immunol, 176, pp.1860~1868 (2006)
- Lazaar AL, "T lymphocytes adhere to airway smooth muscle cells via integrins and CD44 and induce smooth muscle cell DNA synthesis", J Exp Med, 180, pp.807~816 (1994)
- Hakonarson H, "Bi-directional activation between human airway smooth muscle cells and T lymphocytes: role in induction of altered airway responsiveness", J Immunol, 166, pp.293~303 (2001)
- Sukkar MB, "Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle", J Allergy Clin Immunol, 118, pp.641~648 (2006)
- Agrawal S, "Cutting edge:different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos", J Immunol, 171, pp.4984~4989 (2003)
- Eisenbarth SC, "Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen", J Exp Med, 196, pp.1645~1651 (2002)
- Shan X, "Regulation of Toll-like receptor 4-induced proasthmatic changes in airway smooth muscle function by opposing actions of ERK1", 2 and p38MAPK signaling, 2006, pp.291, L324~L333
- Belvisi MG, "Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation", Eur J Pharmacol, 533, pp.101~109 (2006)
- Jiang C, "PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines", Nature, 391, pp.82~86 (1998)
- Bishop-Bailey D, "Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2", J Biol Chem, 274, pp.17042~17048 (1999)
- Rhee CK, "Effect of peroxisome proliferator-activated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma", Int Arch Allergy Immunol, 148, pp.289~296 (2009)
- Shen Y, "PPARγ as a potential target to treat airway mucus hypersecretion in chronic airway inflammatory diseases", PPAR Res, 2012, pp.256874~ (2012)
- Zhu M, "Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells", Am J Respir Cell Mol Biol, 45, pp.111~119 (2011)
- Patel HJ, "Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids : relevance for chronic obstructive pulmonary disease therapy", J Immunol, 170, pp.2663~2669 (2003)
- Ji Y, "PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway", Lab Invest, 89, pp.887~902 (2009)
- Kruger NJ, "The Bradford method for protein quantitation", Methods Mol Biol, 32, pp.9~15 (1994)
- Rhee CK, "Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma", Int Arch Allergy Immunol, 155, pp.243~251 (2011)
- Inoue H, "Feedback control of cyclooxygenase-2 expression through PPARgamma", J Biol Chem, 275, pp.28028~28032 (2000)
- Trifilieff A, "PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect", Br J Pharmacol, 139, pp.163~171 (2003)
- Honda K, "Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model", J Allergy Clin Immunol, 113, pp.882~888 (2004)
- Lee KS, "PPAR-gamma modulates allergic inflammation through up-regulation of PTEN", FASEB J, 19, pp.1033~1035 (2005)
- Sun Y, "PPARγ agonist rosiglitazone suppresses renal mpges-1", pge2 pathway in db, PPAR Res, pp.2013, 2013[DOI]
- Kalinski P, "Regulation of immune responses by prostaglandin E2", J Immunol, 188, pp.21~28 (2012)
- Scher JU, "The anti-inflammatory effects of prostaglandins", J Investig Med, 57, pp.703~708 (2009)
- Fogli S, "Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation", Br J Pharmacol, 168, pp.266~275 (2013)
- Stephen J, "PPAR ligands decrease human airway smooth muscle cell migration and extracellular matrix synthesis", Eur Respir J, 41, pp.425~432 (2013)
- Manuyakorn W, "Airway remodelling in asthma and novel therapy", Asian Pac J Allergy Immunol, 31, pp.3~10 (2013)
- Zhang LL, "PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells", Cardiovasc Res, 92, pp.484~493 (2011)
- Wu Y, "Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4expression in vascular smooth muscle cells", Brain Res, 1322, pp.102~108 (2010)
- Yin Y, "PPARγ agonists regulate tobacco smoke-induced Toll like receptor 4 expression in alveolar macrophages", Respir Res, 15, pp.28~ (2014)
- Dauphinee SM, "Lipopolysaccharide signaling in endothelial cells", Lab Invest, 86, pp.9~22 (2006)
- Hiatt WR, "The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience", N Engl J Med, 369, pp.1285~1287 (2013)
- Home PD, "Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial", Lancet, 373, pp.2125~2135 (2009)